Brian Cheng
Stock Analyst at JP Morgan
(1.10)
# 3,673
Out of 4,944 analysts
65
Total ratings
35.29%
Success rate
-16.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMVT Immunovant | Maintains: Overweight | $40 → $37 | $16.05 | +130.53% | 3 | Aug 12, 2025 | |
| IMNM Immunome | Maintains: Overweight | $23 → $22 | $10.34 | +112.77% | 3 | Aug 7, 2025 | |
| ALLO Allogene Therapeutics | Downgrades: Neutral | n/a | $1.07 | - | 4 | Aug 4, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Neutral | $15 → $8 | $10.11 | -20.83% | 4 | May 13, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $41 | $25.52 | +60.66% | 1 | May 2, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | n/a | $41.33 | - | 1 | Mar 27, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $53 → $57 | $56.45 | +0.97% | 5 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Neutral | $45 → $13 | $11.25 | +15.56% | 4 | Feb 28, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Underweight | n/a | $4.46 | - | 2 | Jan 30, 2025 | |
| EDIT Editas Medicine | Downgrades: Underweight | n/a | $3.00 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $18 | $13.63 | +32.06% | 2 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $28 | $8.03 | +248.69% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $3.28 | +906.10% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $2.02 | +197.03% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.89 | - | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $125 | $6.24 | +1,903.21% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $11.83 | +26.80% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.38 | +3,580.34% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.19 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.66 | +809.09% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.53 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.96 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $18.48 | +359.96% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $8.55 | +145.76% | 1 | Aug 3, 2021 |
Immunovant
Aug 12, 2025
Maintains: Overweight
Price Target: $40 → $37
Current: $16.05
Upside: +130.53%
Immunome
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $10.34
Upside: +112.77%
Allogene Therapeutics
Aug 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.07
Upside: -
iTeos Therapeutics
May 13, 2025
Downgrades: Neutral
Price Target: $15 → $8
Current: $10.11
Upside: -20.83%
CG Oncology
May 2, 2025
Initiates: Overweight
Price Target: $41
Current: $25.52
Upside: +60.66%
Ascentage Pharma Group International
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $41.33
Upside: -
Protagonist Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $56.45
Upside: +0.97%
Intellia Therapeutics
Feb 28, 2025
Downgrades: Neutral
Price Target: $45 → $13
Current: $11.25
Upside: +15.56%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Underweight
Price Target: n/a
Current: $4.46
Upside: -
Editas Medicine
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $3.00
Upside: -
Dec 16, 2024
Upgrades: Overweight
Price Target: $18
Current: $13.63
Upside: +32.06%
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $8.03
Upside: +248.69%
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $3.28
Upside: +906.10%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $2.02
Upside: +197.03%
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $1.89
Upside: -
Mar 19, 2024
Upgrades: Neutral
Price Target: $125
Current: $6.24
Upside: +1,903.21%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $11.83
Upside: +26.80%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.38
Upside: +3,580.34%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.19
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.66
Upside: +809.09%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $1.53
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $1.96
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $18.48
Upside: +359.96%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $8.55
Upside: +145.76%